Board of Directors

Beth Seidenberg, MD

Partner, Kleiner Perkins Caufield & Byers

Carl L. Gordon, PhD, CFA

Partner, OrbiMed

Min Cui, PhD

Founder and Managing Director, Decheng Capital

Naiyer Rizvi, MD

Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Columbia University

Pierre Legault

Independent Director

Stella Xu, PhD

Managing Director, Quan Capital

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer, ARMO BioSciences


Beth Seidenberg, MD

Partner, Kleiner Perkins Caufield & Byers

Dr. Beth Seidenberg focuses on life science investing in digital health and biotech and works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining Kleiner Perkins Caufield & Byers in 2005, Beth has incubated five companies and was the founding CEO of two. She serves on the board of directors of 5 Digital Health Companies: Auxogyn, Mango Health, RedBrick Health, Practice Fusion and Spruce Health and 9 Biotech Companies: 3-V Biosciences, ARMO Biosciences, ACIR Biosciences, Breathe Technologies, Flexus and True North, including 3 publicly traded companies: Atara Bio (ATRA), Epizyme (EPZM) and Tesaro (TSRO). Before joining KPCB, Beth was senior vice president of development and chief medical officer of Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Co. and Merck & Co., Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth grew up in New York and received her B.S. degree from Barnard College and her M.D. from the University of Miami. She completed her post-graduate training at Johns Hopkins University, George Washington University and the National Institutes of Health.

Carl L. Gordon, PhD, CFA

Partner, OrbiMed

Carl is a founding Partner and Co-Head of Global Private Equity at OrbiMed. Mr. Gordon is active in both private equity and small-capitalization public equity investments. He was a senior biotechnology analyst at Mehta and Isaly from 1995 to 1997. He was a Fellow at The Rockefeller University from 1993 to 1995. Mr. Gordon received a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology. His doctoral work involved studies of protein folding and assembly. He received a bachelors degree from Harvard College.

Min Cui, PhD

Founder and Managing Director, Decheng Capital

Dr. Min Cui is the Founder and Managing Director of Decheng Capital. Prior to founding Decheng Capital in 2011, Dr. Cui was an Investment Partner at Bay City Capital, a leading international life science venture capital firm, and focused on evaluating investment opportunities as well as its initiatives in China. Dr. Cui was previously Director of Strategic Investment for the Southern Research Institute, an organization that discovered and developed six anti-cancer drugs that approved by the US Food and Drug Administration. Prior to that, Dr. Cui co-founded Pan Pacific Pharmaceuticals and Hucon Biopharmaceuticals. He served as the Chief Scientific Officer and Executive Vice President of Pan Pacific Pharmaceuticals from 1998 to 2002 and Chief Executive Officer and President of Hucon Biopharmaceuticals from 2003 to 2005, respectively. In these positions, he led efforts in discovery and development of several key technologies in the fields of oncology, cardiology, infectious and inflammatory diseases. Dr. Cui is a member of the board of directors of Accuragen, Ariagen, CardioMed, EpiMab, GenapSys, GeneMDx, GRAIL (observer), Hummingbird, Ketai Medical, Levitas, and Sinomed. His investment portfolio also includes 3SBio (HK stock exchange: 1530), China Biologic Products (NASDAQ: CBPO), Cirina (acquired by GRAIL), Epizyme (NASDAQ: EPZM), GeneWeave Biosciences (acquired by Roche for $425M), GenturaDx (acquired by Luminex), Ion Torrent Systems (acquired by Life Technologies for $725M), and GenturaDx (acquired by Luminex). Dr. Cui was also a co-founder of CNetwork, a San Francisco based non-profit organization dedicated to serving Chinese communities in North America. He received his PhD in Cancer Biology from Stanford University, and his BS in Molecular Biology from Peking University.

Naiyer Rizvi, MD

Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy, Columbia University

Dr. Rizvi has over 20 years of experience in clinical and translational research. His research focus is in lung cancer and immunotherapeutic drug development. He is presently Professor of Medicine at Columbia University where he holds the Price Chair for Clinical Translational Medicine. He is Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy at Columbia. From 2002-2015, he worked at Memorial Sloan Kettering Cancer Center where he led lung cancer immunotherapy research and was an active member of the early immunotherapy drug development program. He earned his MD from University of Manitoba where he also did his Internal Medicine Residency. Dr. Rizvi obtained his Fellowship in Oncology from Beth Israel Hospital, Harvard Medical School.

Pierre Legault

Independent Director

Mr. Legault has over 25 years of executive leadership experience in the biopharmaceutical industry. Most recently, he served as Chief Executive Officer of NephroGenex from 2014 to 2016 and has served as Chairman of the Board since 2012. From 2010 to 2012, Mr. Legault was the Chief Executive officer of Prosidion. Previously, he was the Executive Vice President, Chief Financial Officer, and Treasurer of OSI Pharmaceuticals from 2009 to 2010. In addition, Mr. Legault was the Senior Executive Vice President and Chief Administrative Officer of Rite Aid Corporation from 2006 to 2008 and President of Brooks Eckerd, which was acquired by Rite Aid. Earlier in his career, Mr. Legault worked for Sanofi-Aventis and predecessor companies over a 16 year period in several leadership positions, including President of Worldwide Dermatology Operations and Chief Financial Officer. Mr. Legault received a B.A.A. in Finance, Marketing and Accounting, as well as C.A., and C.P.A. certifications, from HEC Montreal. In addition, he earned an M.B.A. from McGill University and completed an executive master’s program at Harvard Business School.

Stella Xu, MD

Managing Director, Quan Capital

Dr. Stella Xu has over 20 years of experience in the biopharmaceutical industry. She is a Managing Director of Quan Capital, a life sciences venture fund with offices in China & the United States, and has deep expertise in cross board value creation and global investments. Prior to Quan, Stella was Vice President & Site Head of Roche Innovation Center Shanghai, and a core member of the global management team for Roche’s Immunology, Inflammation & Infectious Diseases Discovery and Translation Area. She led the integrated research and early development site in China to discover and develop innovative medicines for global patients. Stella also established the Roche Partnering office in Shanghai and managed business development and licensing activities in APAC (ex-Japan) from 2008 to 2012. Prior to her leadership roles in Asia, she managed global due diligence transaction activities and key alliances across disease areas in Roche Partnering US. Stella joined Roche from McKinsey where she led consulting engagements with healthcare clients in diverse functional areas. Earlier in her career, Stella worked in biotech drug discovery in oncology & inflammation. Stella received her Ph.D. in Immunology from Northwestern University, and her B.S. in Biophysics from Peking University.

Peter Van Vlasselaer, PhD

Founder, President and Chief Executive Officer, ARMO BioSciences

Peter Van Vlasselaer, PhD has over 20 years of experience in the biotech industry and is currently CEO of ARMO BioSciences. Previously, he was CEO of iPierian, ARRESTO and AVIDIA. In addition to founding ARMO, Dr. Van Vlasselaer was a co-founder of Arresto, TrueNorth and ACIR BioSciences and he was a member of the start-up teams of InterMune (ITMN) and Dendreon (DNDN). He currently serves on the boards of ARMO, Blade Therapeutics and TM3 Therapeutics. Dr. Van Vlasselaer was a post-doctoral fellow in the division of Immunology and Rheumatology at the Stanford University and at the Laboratory of Human Immunology at DNAX Research Institute, both in Palo Alto, CA. Dr. Van Vlasselaer has a bachelor degree in Zoology and a PhD in Immunology from the Catholic University of Leuven, Belgium. He has authored several peer reviewed scientific publications and book chapters and he is an inventor on multiple patents.